P53-associated lncRNAs regulate immune functions and RNA-modifiers in gastric cancer
Author:
Huanjie Zhao,
Bukhari IhtishamORCID,
Fazhan Li,
Wen Huijuan,
Wang Jingyun,
Wanqing Wu,
Yuming Fu,
Youcai Tang,
AlJowaie Reem M.,
Aziz Ibrahim M.,
Xiufeng Chu,
Yang Mi,
Pengyuan Zheng
Reference83 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018
2. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Kang;Lancet,2017
3. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial;Fuchs;JAMA Oncol.,2018
4. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype;Ferro;Eur. J. Cancer,2014
5. Epigenetic biomarkers in gastrointestinal cancers: the current state and clinical perspectives;Vedeld;Semin. Cancer Biol.,2018